Distinct Epitopes for Anti–Glomerular Basement Membrane Alport Alloantibodies and Goodpasture Autoantibodies within the Noncollagenous Domain of α3(IV) Collagen: A Janus-Faced Antigen : Journal of the American Society of Nephrology

Journal Logo

Basic Immunology and Pathology

Distinct Epitopes for Anti–Glomerular Basement Membrane Alport Alloantibodies and Goodpasture Autoantibodies within the Noncollagenous Domain of α3(IV) Collagen

A Janus-Faced Antigen

Wang, Xu-Ping*; Fogo, Agnes B.; Colon, Selene*; Giannico, Giovanna; Abul-Ezz, Sameh R.; Miner, Jeffrey H.§; Borza, Dorin-Bogdan*

Author Information
Journal of the American Society of Nephrology 16(12):p 3563-3571, December 2005. | DOI: 10.1681/ASN.2005060670
  • Free


The α3α4α5(IV) collagen network is a major component of the glomerular basement membrane (GBM), which is necessary for the long-term preservation of glomerular ultrafiltration function. Alport syndrome, the most frequent form of hereditary glomerulopathy, is caused by mutations in the genes encoding α3-α5(IV) collagen chains, which prevent a developmental switch from the embryonic α1α2(IV) collagen network to the adult α3α4α5(IV) collagen in specialized basement membranes (1, 2). The majority of Alport cases (>85%) are X-linked (XLAS), as a result of mutations in the COL4A5 gene encoding α5(IV) collagen (3). A small proportion of patients develop autosomal recessive Alport syndrome (ARAS), as a result of mutations in both alleles of COL4A3 or COL4A4 genes (4, 5). Over time, the Alport GBM undergoes characteristic ultrastructural changes, and patients develop hematuria and proteinuria and slowly progress toward ESRD, requiring dialysis or transplantation (6).

Among Alport patients that receive a kidney transplant, approximately 3 to 5% develop posttransplantation anti-GBM glomerulonephritis mediated by alloantibodies that bind to the allograft GBM but not to the Alport GBM (7, 8). Alloantibodies were shown to react with the noncollagenous (NC1) domains of type IV collagen isoforms that are present in normal but not Alport kidneys (9). In general, patients with XLAS develop alloantibodies to the α5NC1 domain (1012), and patients with ARAS develop alloantibodies against the α3NC1 domain (12, 13). Both α3NC1 and α5NC1 occur natively as subunits of an (α3α4α5)2 NC1 hexamer (14), formed by the head-to-head association of two triple-helical α3α4α5(IV) collagen molecules in the GBM.

Alport posttransplantation anti-GBM nephritis in the renal allograft follows a similar clinical course as autoimmune anti-GBM disease, which is mediated by Goodpasture (GP) autoantibodies that recognize the NC1 domain of the α3(IV) collagen chain (15). Together, these forms of anti-GBM disease provide a rare example of pathogenic autoantibodies and alloantibodies that target a common antigen. A detailed comparison between Alport alloantibodies and GP autoantibodies therefore could provide new insights into the molecular mechanisms underlying the cause and pathogenesis of anti-GBM disease, which may help to identify new therapies or preventive interventions.

The B cell epitopes targeted by GP autoantibodies have been characterized in detail (1620), and two major conformational GP autoepitopes have been mapped to residues 17 to 31 (EA) and 127 to 141 (EB) of the α3NC1 domain (18, 19). The location of alloepitopes within α3NC1 and α5NC1 has not yet been determined. Here, we characterized the specificity of anti-GBM alloantibodies eluted from the renal allograft of a patient who had ARAS and developed posttransplantation anti-GBM glomerulonephritis that ultimately led to the loss of allograft. ARAS alloantibodies specifically bound the α3NC1 and α4NC1 domains and recognized a noncontiguous α3NC1 alloepitope distinct from the GP autoepitopes. The alloantibody specificity indicated a selective lack of immune tolerance toward the α3 and α4(IV) collagen chains absent in ARAS. Using COL4A3−/− mice, an animal model of ARAS (21, 22), we further showed that the specificity of anti-GBM antibodies is critically influenced by the identity of the antigen used for immunization. Overall, the results suggest that distinct molecular forms of α3(IV) collagen cause ARAS posttransplantation anti-GBM nephritis and autoimmune anti-GBM disease.

Materials and Methods

Patients and Sera

A 28-yr-old Asian woman with ESRD secondary to ARAS underwent a kidney transplant at age 18, which failed 6 mo later as a result of reported occurrence of anti-GBM disease. In May 2002, the patient received a second cadaveric kidney transplant. Her immunosuppression regimen consisted of prednisone, mycophenolate mofetil, and tacrolimus. Initial renal function was excellent (serum creatinine 0.8 mg/dl) but worsened after 20 d (serum creatinine 1.5 mg/dl), and a percutaneous renal transplant biopsy was performed. The first renal biopsy contained 14 normal-appearing glomeruli. The interstitium showed a patchy lymphoplasmacytic infiltrate involving slightly less than 5% of the nonscarred parenchyma, with occasional PMN and eosinophils, with minimal tubulitis, and mild interstitial edema and hemorrhages. Arteries were unremarkable, without endothelialitis. Less than 5% of the tubulointerstitium was scarred. Immunofluorescence (IF) staining for IgG showed 1 to 2+ linear glomerular and focal linear tubular basement staining; C3 showed weaker (1+) staining with a pattern similar to IgG, as did κ and λ light chains (trace to 1+). Staining for IgA, IgM, C1q, fibrinogen, and albumin was negative or nonspecific. Electron microscopy showed only minimal effacement of foot processes and mild increase in mesangial matrix. A diagnosis of minimal infiltrate, not sufficient to diagnose acute rejection, was made, and anti-GBM staining was noted but without evidence of associated tissue injury.

The patient was treated with intravenous methylprednisolone sodium succinate and tacrolimus dose was increased, but serum creatinine persisted at 1.6 mg/dl. A second percutaneous transplant biopsy that was performed 1 wk later contained two glomeruli, one of which showed a small area of segmental necrosis with a small incipient cellular crescent (Figure 1A). The tubulointerstitium showed scattered lymphocytic infiltrate and mild edema. IF showed 2 to 3+ linear glomerular and focal 2+ tubular linear basement membrane staining for IgG (Figure 1B), κ and λ light chains, and a similar pattern for C3 (2+ in GBM; 1+ in tubular basement membranes). Other stains were negative or nonspecific. Electron microscopy studies were not performed. A diagnosis of anti-GBM antibody-mediated glomerulonephritis was made. Serum anti-GBM antibodies, initially below detection levels, became detectable but at low titer (1:32). Plasmapheresis was initiated, and mycophenolate mofetil was replaced with Cytoxan 2 mg/kg. Serum creatinine stabilized at a new baseline of 1.8 mg/dl until 3 mo posttransplantation. Serum creatinine rose to 2.9 mg/dl, and a third percutaneous renal biopsy was performed in September 2002. Thirteen of 17 glomeruli present showed global or near global sclerosis with extensive mostly fibrocellular and fibrous crescents and three cellular crescents, with fibrinoid necrosis in one of these glomeruli (Figure 1C). Interstitial fibrosis was approximately 50%, with proportional lymphocytic infiltrate without evidence of rejection. Vessels were unremarkable without endothelialitis. IF again showed strong linear glomerular and focal linear tubular basement staining for IgG (2 to 3+) and C3 (1 to 2+). Fibrinogen stained positively in crescents. Other stains were negative. A diagnosis of anti-GBM antibody-mediated glomerulonephritis with crescents and necrotizing lesions was made. While receiving plasmapheresis, the patient was admitted to the hospital with change in mental status, later diagnosed as West Nile virus encephalitis. Immunosuppression was withdrawn, and the patient died several months later. An autopsy was not performed.

Kidney-bound anti-GBM alloantibodies were eluted from the frozen portions of the three combined renal biopsies. Wet tissue was homogenized, washed with cold PBS, and eluted with 0.1 M glycine at pH 2.8 and then pH 2.2. The acid eluates were pooled, neutralized with 0.1 volumes of 1 M Tris buffer (pH 8.0), and analyzed by Western blot and indirect ELISA. Patient serum was not available for analysis. Sera or the first plasmapheresis fluid from patients with biopsy-proven autoimmune anti-GBM disease was used as a source of GP autoantibodies. Some of these sera were previously described (18), and additional GP sera were purchased from Wieslab AB (Lund, Sweden). All GP sera reacted specifically with r-α3NC1 monomers and α3NC1 chimeras that contained the EA and/or EB epitopes (see below).


NC1 hexamers of collagen IV were collagenase-solubilized from human kidney cortex basement membranes and purified as described (23). Human GBM NC1 hexamers were fractionated into (α3α4α5)2, (α1)2/(α5)6, and (α1α2α1)2 NC1 hexamers by affinity chromatography on specific immobilized mAb, and their composition was verified by Western blot, as reported (14). Recombinant human α1-α5NC1 domains and chimeric α1/α3NC1 domains were expressed in human kidney 293 cells for correct folding and purified by affinity chromatography on immobilized anti-FLAG mAb (18). The chimeras consisted of an α1NC1 scaffold onto which the following α3NC1 residues were substituted: 17 to 31 (C2), 90 to 104 (C5), 127 to 141 (C6), 1 to 14 plus four amino-terminal Gly-X-Y triplets (C7), and 197 to 232 (C8). Composite chimera C26 contained both α3NC1 sequences found in chimeras C2 and C6. Mab3, a mouse IgG mAb specific for the α3(IV)NC1 domain, was purchased from Wieslab AB.

ELISA Immunoassays

For indirect ELISA, Maxisorp microtiter plastic plates were coated overnight with purified antigens (250 ng/well) in carbonate buffer (pH 9.6) and blocked with 1% BSA. Immobilized proteins were incubated with diluted anti-GBM sera or eluted alloantibodies for 1 h, and IgG binding was detected with alkaline phosphatase–conjugated secondary antibodies followed by chromogenic substrate. The absorbance at 405 nm was measured with a Spectramax 190 ELISA plate reader (Molecular Devices, Sunnyvale, CA). The graphs show the mean absorbance and SD of three measurements. Comparisons between groups were performed by t test. P < 0.05 were considered significant. For inhibition ELISA, diluted GP sera or anti-α3NC1 mAb were preincubated for 2 h at room temperature with soluble antigens before assaying binding to immobilized r-α3NC1 in duplicate samples.

Western Blot

Purified human GBM hexamers (400 ng/lane) were separated by SDS-PAGE in 6 to 20% gradient gels and transferred to Immobilon P. Membranes were blocked with 5% casein, incubated overnight with eluate or control sera diluted in incubation buffer, then alkaline phosphatase–conjugated anti-human IgG antibody and chromogenic substrate.

Production of Anti-GBM Antibodies in Mice

All mouse experiments were approved by the Institutional Animal Care and Use Committee at Vanderbilt University. Congenic C57Bl/6 COL4A3−/− mice originally generated by Dr. Jeffrey Miner (24) were maintained in the Animal Facility at Vanderbilt University. Mouse GBM NC1 hexamers were prepared from wild-type mouse kidneys, as described for human NC1 hexamers. COL4A3−/− mice were immunized at 8 to 10 wk of age with (1) 25 μg of r-α3NC1 monomers (n = 5), (2) 100 μg of native mouse GBM hexamers (in PBS, n = 6), and (3) acid-dissociated mouse hexamers (in 0.1 M acetic acid, n = 4). The antigens in 50 μl of buffer were emulsified with an equal volume of complete Freund’s adjuvant (Sigma, St. Louis, MO) and injected subcutaneously at two sites. A booster immunization with the same amount of antigen in incomplete Freund’s adjuvant (Sigma) was given 3 wk later. Deeply anesthetized mice were killed at 12 wk postimmunization, and blood was collected by heart puncture.

Molecular Modeling and Analysis

A molecular model of α3NC1 was built using the ESyPred3D server (25), using as template the x-ray structure of the homologous α1NC1 domain, chain “K” in PDB structure 1M3D (26). The software program Rastop, version 2.0, was used for molecular rendering and measurements of interatomic distances.


ARAS Anti-GBM Alloantibodies Target α3 and α4(IV) Collagen NC1 Domains

The rare availability of frozen renal biopsy specimens from a patient who had ARAS and developed posttransplantation anti-GBM nephritis in the allograft prompted us to investigate the specificity of kidney-bound anti-GBM alloantibodies. Western blot analysis of acid-eluted antibodies from the allograft biopsy revealed IgG binding to the monomer and dimer subunits of NC1 hexamers of type IV collagen from human GBM, similar to human GP autoantibodies (Figure 2A). However, because of the complex composition of this antigen preparation, which comprised a mixture of NC1 monomers and dimers of α1-α6(IV) collagen (14), the specificity of alloantibodies could not be established unambiguously.

The alloantibody specificity was determined by indirect ELISA using purified NC1 hexamers with distinct subunit compositions, fractionated by affinity chromatography on immobilized chain-specific mAb as described previously (14). Eluted anti-GBM antibodies reacted with (α3α4α5)2 NC1 hexamers but not with [(α1)2]2 or (α1)2/(α5)6 NC1 hexamers (Figure 2B). To identify which subunits of the α3α4α5 NC1 hexamers are targeted by alloantibodies, we used recombinant human α1-α5 NC1 monomers expressed in human 293 cells in indirect ELISA. Relative to α3α4α5 NC1 hexamers, alloantibodies exhibited strong reactivity toward r-α3NC1 (86%) and moderate reactivity toward r-α4NC1 (46%), whereas binding to r-α5NC1, r-α1NC1, and r-α2NC1 was NS (<15%, comparable to α1α2 NC1 hexamers). Thus, the ARAS alloantibodies target primarily the α3NC1 subunits of α3α4α5 NC1 hexamers and have weaker reactivity toward the α4NC1 subunits.

Anti-α3(IV)NC1 Alloantibodies Recognize a Noncontiguous Epitope

The finding of alloantibodies reactive with human α3NC1 but not α1NC1 monomers provided a direct strategy to map the α3NC1 alloepitopes using chimeric α1/α3NC1 constructs. Chimeras that contain short regions of α3NC1 substituted onto an α1NC1 scaffold for correct folding of conformational epitopes have been previously used to map the α3NC1 autoepitopes of GP autoantibodies (18, 19). By indirect ELISA using a panel of α1/α3 chimeras (Figure 3), alloantibodies reacted only with a composite chimera, C26, which contained two noncontiguous α3NC1 sequences, EA and EB. Because alloantibodies did not bind significantly to the C2 and C6 chimeras that contained the isolated EA and EB sequences, both regions must jointly form a composite α3NC1 alloepitope. Importantly, the same epitope specificity has been previously found for Mab3 (19), a well-characterized mouse anti-α3NC1 mAb produced against NC1 hexamers from bovine GBM (27).

GP Autoantibodies and ARAS Alloantibodies Target Distinct α3NC1 Epitopes

Remarkably, each of the two α3NC1 sequences harbored by the C26 chimera (EA and EB) encompasses separate B cell epitopes, recognized by human GPA, GPB, and GPAB autoantibodies (19). ARAS alloantibodies were distinguished from GPA, GPB, or GPAB autoantibodies by their lack of reactivity toward C2 and C6 chimeras that contained individual autoepitopes (see Table 1). ARAS alloantibodies were further distinguished from GPX autoantibodies because the latter did not react with C26 chimera. However, previous studies of the epitope specificity of human GP antibodies have not entirely ruled out the possibility that autoimmune GP sera may contain autoantibodies against the composite α3NC1 alloepitope, EA&B. Because in standard immunoassays the putative GP reactivity against the composite α3NC1 alloepitope would be masked by the binding of GPA and GPB autoantibodies to the individual EA and EB epitopes, a different strategy was necessary to address this possibility.

The presence of GP autoantibodies against a composite EA&B epitope was assayed by inhibition ELISA, comparing antibody binding with immobilized α3NC1 in the presence of soluble chimeras. For comparison, Mab3, which targets a composite α3NC1 epitope similar or identical to that of ARAS alloantibodies, was inhibited only by the composite chimera C26 but not by the combination of single chimeras C2 and C6 (Figure 4A). In contrast, the inhibition of human GP autoantibodies by the C26 chimera was indistinguishable from the combined effect of C2 and C6 chimeras (Figure 4B). These results were confirmed using GP sera from 11 patients (Figure 5). Thus, GP sera do not contain autoantibodies against the composite α3NC1 alloepitope EA&B. Overall, the results indicate that human Alport alloantibodies and GP autoantibodies have distinct specificities, despite targeting epitopes within a narrow region of α3(IV) collagen.

Distinct Locations of α3NC1 Alloepitopes and Autoepitopes

Even though the EA and EB regions are separated by approximately 100 residues in the primary structure of α3NC1, they are adjacent in the tertiary structure, as shown by a structural model of the α3NC1 domain build based on its homology to α1NC1 domain within the crystal structure of the [(α1)2]2 hexamer (Figure 6). Therefore, the noncontiguous epitopes of ARAS alloantibodies and Mab3 must include residues from both EA and EB regions that are located in close proximity to each other. An analysis of the α3NC1 model revealed that residues 20 to 26 of the EA region and 137 to 141 of the EB region were within <10 A[Combining Ring Above] of each other. Moreover, these residues mapped to an accessible location on the surface of the NC1 hexamer, and none was in close proximity (>10 A[Combining Ring Above]) to the flanking NC1 domains in the hexamer complex (Figure 6). The accessibility of the composite epitope is further supported by Mab3 binding to native α3α4α5 NC1 holo-hexamers (23), similar to XLAS alloantibodies (19, 28). In contrast, the epitopes of all GP antibody subsets are cryptic and inaccessible for autoantibody binding unless the hexamer is dissociated (19, 29). The most likely explanation for the crypticity of GP epitopes is steric hindrance of key epitope residues by the flanking α4NC1 and α5NC1 domains (14, 29). Indeed, among the four EA residues identified in the epitope of immunodominant GPA antibodies (30), none is proximal to the EB region, whereas two are adjacent (within 10 A[Combining Ring Above]) to the α5NC1 domain (Figure 6). Overall, the molecular architecture of the α3NC1 epitopes suggests that exposed epitopes within the native NC1 hexamers are alloantigenic, being targeted by alloantibodies in posttransplantation anti-GBM nephritis, whereas cryptic epitopes within isolated α3NC1 subunits are autoantigenic, being targeted by autoantibodies in autoimmune anti-GBM disease.

Different Molecular Forms of α3NC1 Antigen Elicit Anti-GBM Antibodies with Distinct Specificities in COL4A3−/− Alport Mice

To gain further insight into the nature of the antigen that triggers production of posttransplantation anti-GBM alloantibodies, we used a mouse model of ARAS (22). We hypothesized that native NC1 hexamers would elicit mouse anti-GBM antibodies similar to human ARAS alloantibodies, whereas isolated NC1 subunits would induce mouse anti-GBM antibodies similar to human GP autoantibodies. COL4A3−/− mice were immunized with native and acid-dissociated NC1 hexamers that were isolated from wild-type mouse GBM, as well as with r-α3NC1 monomers. All antigens elicited mouse IgG antibodies that reacted strongly with murine α3α4α5 (but not α1α2) NC1 hexamers but were distinguished by their reactivity toward α3NC1 monomers (Figure 7A). Mice that were immunized with r-α3NC1 monomers produced the highest titers of anti-α3NC1 antibodies. These antibodies reacted mainly with epitopes in the C2 and C6 chimeras (Figure 7B), therefore recapitulating the specificity of human GP autoantibodies. Surprisingly, murine antibodies to native hexamers had very low reactivity toward all NC1 monomers; some sera exhibited weak binding to α3NC1 but not significantly higher than binding to α1NC1 monomers (thereby precluding epitope mapping). Antibodies in this group were least similar to human anti-GBM antibodies. It is interesting that mice that were immunized with acid-dissociated hexamers did produce antibodies that selectively targeted α3NC1 monomers (Figure 7A), even though the immunogen comprised a mixture of α1-α5 NC1 domains that contained only approximately 10% α3NC1 (data not shown); this specificity most likely reflects the lack of immune tolerance toward α3(IV) collagen in COL4A3−/− mice, as noted for human ARAS. However, unlike murine antibodies to α3NC1 monomers, anti-α3NC1 antibodies from mice that were immunized with dissociated hexamers did not react with the C2 and C6 chimeras (Figure 7B), being similar in this respect to human ARAS alloantibodies. These results demonstrate that anti-GBM antibodies with distinct epitope specificities are induced by different molecular forms of the α3NC1 antigen.


GP autoimmune disease and Alport posttransplantation anti-GBM nephritis are distinct forms of anti-GBM antibody disease that implicate a common antigen, the NC1 domains of the α3α4α5(IV) collagen network. This provides a rare opportunity to establish whether differences in the immune setting (normal expression of autoantigen versus its absence in genetic disease) can shape the fine specificity of human anti-GBM antibodies. GP autoantibodies bind to conformational autoepitopes within the α3NC1 domain, previously identified using chimeric α1/α3 NC1 domains. In this study, using the same chimeric constructs, we established for the first time the epitope specificity of anti-α3NC1 alloantibodies, which were eluted from the renal allograft of one patient who had ARAS and developed severe posttransplantation anti-GBM antibody nephritis. We show that ARAS alloantibodies and GP autoantibodies bind distinct alloepitopes and autoepitopes within α3NC1. For comparison, inhibitory anti–factor VIII alloantibodies and autoantibodies from patients with congenital or acquired hemophilia A both target common immunodominant epitopes within the A2 and C2 domains of factor VIII (31, 32). Hence, α3(IV) collagen is the first human pathogenic antigen shown to harbor distinct alloepitopes and autoepitopes—thus, a “Janus-faced” antigen.

The chain and epitope specificity of kidney-eluted ARAS alloantibodies characterized in this work suggests a selective lack of immune tolerance toward collagen IV chains and networks that are not expressed in patients with ARAS. The alloantibodies reacted specifically with the NC1 hexamers of the α3α4α5(IV) collagen network, which is absent in Alport syndrome, but not with NC1 hexamers derived from the α1α2(IV) or α1α2/α5α6(IV) networks, normally expressed in ARAS (33, 34). The major target of kidney-bound ARAS alloantibodies is the α3NC1 subunit of the α3α4α5NC1 hexamer. This is not unexpected, because anti-α3NC1 antibodies have been repeatedly found in the sera of patients with ARAS posttransplantation nephritis (12, 13, 35). The α4NC1 domain is a novel, albeit minor, target of ARAS alloantibodies. Anti-α4NC1 alloantibodies have been previously described in the sera of three patients with XLAS and posttransplantation nephritis (35). Lack of reactivity toward the α5NC1 subunit suggests that central and/or peripheral immune tolerance toward the α5(IV) collagen may be established in ARAS because this chain remains part of the unaffected α1α2/α5α6(IV) collagen network.

The presence or absence of immune self-tolerance toward α3(IV) collagen further affects the epitope specificity of anti-GBM antibodies. GP autoantibodies preferentially target α3NC1 autoepitopes that are structurally sequestered within the native NC1 hexamers but not exposed α3NC1 epitopes (19). Therefore, an autoimmune response may be triggered upon unmasking of cryptic neo-epitopes by putative pathogenic factors that affect the hexamer structure, which provide a mechanism for circumventing the normal self-tolerance toward native antigen. In contrast, in ARAS, lack of tolerance toward the α3(IV) and α4(IV) collagen chains would allow production of alloantibodies against exposed α3NC1 alloepitopes.

Characterization of anti-GBM antibodies produced in COL4A3−/− mice suggests that the molecular form of the α3NC1 antigen is an additional factor modulating the specificity of anti-GBM antibodies. Only α3NC1 monomers elicited murine antibodies with similar specificity to human GP autoantibodies, thus implicating α3NC1 monomers as the antigen initiating autoimmune anti-GBM disease. Consistent with this paradigm, GP antibodies were shown to target preferentially a subset of M-α3α4α5 NC1 hexamers composed of monomer subunits only, inducing hexamer dissociation upon binding (29). Surprising, immunization with acid-dissociated rather than native NC1 hexamers induced production of mouse antibodies most closely resembling human ARAS alloantibodies and Mab3. This unexpected finding suggests that molecular damage to α3α4α5(IV) NC1 hexamers in the allograft GBM could be an important factor that triggers Alport posttransplantation anti-GBM glomerulonephritis.

ARAS alloantibodies that are characterized in this work were likely pathogenic, because they were eluted from a renal allograft with characteristic crescentic injury. However, patients who have Alport syndrome and receive a transplant may often exhibit linear IgG deposition in the allograft GBM (3538) and/or circulating anti-GBM alloantibodies (35) in the absence of nephritis. Although nonpathogenic alloantibodies were not available for this study, further investigations comparing the properties of nephritogenic and non-nephritogenic Alport anti-GBM alloantibodies may provide a better understanding of the triggers and mechanisms that cause allograft nephritis in a small proportion of Alport transplant recipients. The findings presented herein represent the analysis of allograft-bound alloantibodies from a single patient with ARAS and posttransplantation anti-GBM glomerulonephritis. Because results may vary among different patients, future studies of circulating and kidney-bound alloantibodies from other patients with Alport posttransplantation nephritis are necessary to establish definitively the repertoire of specificities for anti-GBM alloantibodies.

A detailed knowledge of the collagen IV chains and epitopes that are targeted by pathogenic anti-GBM alloantibodies may lead to the development of preemptive therapeutic strategies aimed specifically at inducing immune tolerance in patients with Alport syndrome before a renal transplant. In rat and mouse models of GP disease, oral administration of autoantigen before immunization blunts the severity of anti-GBM nephritis by reducing the Th1 response (39, 40). Such proactive intervention may be beneficial in the subgroup of patients who have Alport syndrome and are at risk for developing posttransplantation nephritis. Even though this complication affects a small proportion of Alport transplant recipients, its incidence in this group far exceeds that of autoimmune anti-GBM disease in the general population (estimated at 0.5 to 1 new cases per 1,000,000 people per year). Future studies in animal models of Alport syndrome will be instrumental for understanding how immune tolerance to α3α4α5(IV) collagen is established and broken and how it can be modulated for therapeutic purposes.

Figure 1:
Histopathologic findings in the renal allograft biopsy of the patient with autosomal recessive Alport syndrome (ARAS). (A) Segmental necrosis and epithelial cell activation in a glomerulus (hematoxylin and eosin). (B) Linear glomerular basement membrane (GBM) staining with anti-IgG antibody (immunofluorescence). (C) Fibrocellular crescent and severe tubulointerstitial fibrosis (periodic acid-Schiff). Magnification, ×200.
Figure 2:
Characterization of kidney-bound ARAS alloantibodies by Western blot and indirect ELISA. (A) Western blot analysis of eluted ARAS alloantibodies (a), Goodpasture (GP) autoantibodies (b), and negative control serum (c), revealing IgG binding to noncollagenous (NC1) monomer (M) and dimer (D) subunits of total human GBM hexamers. (B) Chain specificity of ARAS alloantibodies. IgG binding to affinity-purified human NC1 hexamers and recombinant NC1 monomers (250 ng/well) was measured by indirect ELISA. *Significantly higher reactivity (P < 0.05 by t test) relative to the α1α2 NC1 hexamers.
Figure 3:
Epitope specificity of anti-α3NC1 ARAS alloantibodies. IgG binding to immobilized α1/α3 chimeras (250 ng/well) was measured by indirect ELISA. *Significantly higher reactivity (P < 0.05 by t test) relative to the α1NC1 domain.
Figure 4:
Inhibition ELISA analysis of the specificity of anti-α3NC1 antibodies. Binding of Mab3 (A) or GP antibodies (B) to immobilized r-α3NC1 monomers (50 ng/well) was inhibited using various concentrations of soluble r-α3NC1 (□) and chimeras C2 (⋄), C6 (▵), a mixture of equal amounts of C2 and C6 (○), and C26 (•).
Figure 5:
Analysis of GP sera by inhibition ELISA. Eleven GP sera were incubated with soluble α3NC1 or chimeras (10 μg/ml), and then binding to immobilized α3NC1 monomers was measured by ELISA. The graph shows means and SEM. Inhibition of GP sera by chimera C26 was not significantly different from that produced by a combination of C2 and C6 chimeras (P = 0.598; paired t test).
Figure 6:
Molecular model depicting the location of α3NC1 alloepitopes and autoepitopes. (Top) A space-filling model depicting half of the α3α4α5 NC1 hexamer. The α3, α4, and α5NC1 residues are shaded in light red, light blue, and light green, respectively. The subset of EA residues within 10 A[Combining Ring Above] of the α5NC1 subunit within the hexamer are shown in blue. EA residues within 10 A[Combining Ring Above] of the EB site formed a distinct subset, shown in green. Other EA residues are shown in gray. The subset of EB residues within 10 A[Combining Ring Above] of the α4NC1 subunit within the hexamer are shown in magenta. EB residues within 10 A[Combining Ring Above] of EA formed a distinct subset, depicted in orange. EA residues within 10 A[Combining Ring Above] of the α5NC1 subunit within the hexamer are shown in blue. (Bottom) Close-up of the EA and EB epitope regions. Residues in the epitope of human GPA autoantibodies (Ala-18, Ile-19, Val-27, Pro-28) are in bold.
Figure 7:
Specificity of murine anti-GBM antibodies. (A) Sera from COL4A3−/− mice that were immunized with native (□) or acid-dissociated mouse NC1 hexamers ( ▨) and r-α3NC1 monomers (▪) were diluted 1:500 and analyzed by indirect ELISA using purified murine NC1 hexamers and recombinant NC1 monomers (each antigen coated at 100 ng/well). Murine α3α4α5 NC1 hexamers were affinity-purified from mouse GBM hexamers, using an anti-α3NC1 mAb; the unbound fraction comprised mouse α1α2 NC1 hexamers. Sera from control mice that were immunized with adjuvant alone had no reactivity (ELISA absorbence < 0.05) against any antigen (data not shown). The bars depict means and SEM for all sera in each group. (B) Epitope specificity of murine anti-α3NC1 IgG antibodies produced against acid-dissociated GBM hexamers (▨) or α3NC1 monomers (▪) was analyzed using α1/α3 chimeras (100 ng/well).
Table 1:
Comparison of human anti-α3NC1 GP autoantibodies and ARAS alloantibodya

This work was supported by grant P01 DK65123 (to D.B.B.) from the National Institutes of Health and by the Carl W. Gottschalk Research Scholar Award from the American Society of Nephrology (to D.B.B.). J.H.M. is an Established Investigator of the American Heart Association.

We are grateful to Dr. Billy G. Hudson for providing the cell lines that express recombinant NC1 domains and α1/α3 chimeras. We thank Parvin Todd for expert technical assistance.

Published online ahead of print. Publication date available at http://www.jasn.org.

X.-P.W. and A.B.F. contributed equally to this work.


1. Miner JH, Sanes JR: Collagen IV alpha 3, alpha 4, and alpha 5 chains in rodent basal laminae: Sequence, distribution, association with laminins, and developmental switches. J Cell Biol127 :879 –891,1994
2. Kalluri R, Shield CF, Todd P, Hudson BG, Neilson EG: Isoform switching of type IV collagen is developmentally arrested in X-linked Alport syndrome leading to increased susceptibility of renal basement membranes to endoproteolysis. J Clin Invest99 :2470 –2478,1997
3. Barker DF, Hostikka SL, Zhou J, Chow LT, Oliphant AR, Gerken SC, Gregory MC, Skolnick MH, Atkin CL, Tryggvason K: Identification of mutations in the COL4A5 collagen gene in Alport syndrome. Science248 :1224 –1227,1990
4. Mochizuki T, Lemmink HH, Mariyama M, Antignac C, Gubler MC, Pirson Y, Verellen-Dumoulin C, Chan B, Schroder CH, Smeets HJ, Reeders ST: Identification of mutations in the alpha 3(IV) and alpha 4(IV) collagen genes in autosomal recessive Alport syndrome. Nat Genet8 :77 –81,1994
5. Lemmink HH, Mochizuki T, van den Heuvel LP, Schroder CH, Barrientos A, Monnens LA, van Oost BA, Brunner HG, Reeders ST, Smeets HJ: Mutations in the type IV collagen alpha 3 (COL4A3) gene in autosomal recessive Alport syndrome. Hum Mol Genet3 :1269 –1273,1994
6. Kashtan CE, Michael AF: Alport syndrome. Kidney Int50 :1445 –1463,1996
7. McCoy RC, Johnson HK, Stone WJ, Wilson CB: Absence of nephritogenic GBM antigen(s) in some patients with hereditary nephritis. Kidney Int21 :642 –652,1982
8. Milliner DS, Pierides AM, Holley KE: Renal transplantation in Alport’s syndrome: Anti-glomerular basement membrane glomerulonephritis in the allograft. Mayo Clin Proc57 :35 –43,1982
9. Kashtan C, Fish AJ, Kleppel M, Yoshioka K, Michael AF: Nephritogenic antigen determinants in epidermal and renal basement membranes of kindreds with Alport-type familial nephritis. J Clin Invest78 :1035 –1044,1986
10. Ding J, Zhou J, Tryggvason K, Kashtan CE: COL4A5 deletions in three patients with Alport syndrome and posttransplant antiglomerular basement membrane nephritis. J Am Soc Nephrol5 :161 –168,1994
11. Dehan P, Van den Heuvel LP, Smeets HJ, Tryggvason K, Foidart JM: Identification of post-transplant anti-alpha 5 (IV) collagen alloantibodies in X-linked Alport syndrome. Nephrol Dial Transplant11 :1983 –1988,1996
    12. Brainwood D, Kashtan C, Gubler MC, Turner AN: Targets of alloantibodies in Alport anti-glomerular basement membrane disease after renal transplantation. Kidney Int53 :762 –766,1998
    13. Kalluri R, van den Heuvel LP, Smeets HJ, Schroder CH, Lemmink HH, Boutaud A, Neilson EG, Hudson BG: A COL4A3 gene mutation and post-transplant anti-alpha 3(IV) collagen alloantibodies in Alport syndrome. Kidney Int47 :1199 –1204,1995
    14. Borza DB, Bondar O, Todd P, Sundaramoorthy M, Sado Y, Ninomiya Y, Hudson BG: Quaternary organization of the Goodpasture autoantigen, the alpha3(IV) collagen chain: Sequestration of two cryptic autoepitopes by intra-protomer interactions with the alpha4 and alpha5 NC1 domains. J Biol Chem277 :40075 –40083,2002
    15. Saus J, Wieslander J, Langeveld JP, Quinones S, Hudson BG: Identification of the Goodpasture antigen as the alpha 3(IV) chain of collagen IV. J Biol Chem263 :13374 –13380,1988
    16. Hellmark T, Segelmark M, Unger C, Burkhardt H, Saus J, Wieslander J: Identification of a clinically relevant immunodominant region of collagen IV in Goodpasture disease. Kidney Int55 :936 –944,1999
    17. Hellmark T, Burkhardt H, Wieslander J: Goodpasture disease. Characterization of a single conformational epitope as the target of pathogenic autoantibodies. J Biol Chem274 :25862 –25868,1999
      18. Netzer KO, Leinonen A, Boutaud A, Borza DB, Todd P, Gunwar S, Langeveld JP, Hudson BG: The Goodpasture autoantigen. Mapping the major conformational epitope(s) of alpha3(IV) collagen to residues 17-31 and 127-141 of the NC1 domain. J Biol Chem274 :11267 –11274,1999
      19. Borza DB, Netzer KO, Leinonen A, Todd P, Cervera J, Saus J, Hudson BG: The Goodpasture autoantigen: Identification of multiple cryptic epitopes on the NC1 domain of the alpha3(IV) collagen chain. J Biol Chem275 :6030 –6037,2000
      20. Gunnarsson A, Hellmark T, Wieslander J: Molecular properties of the Goodpasture epitope. J Biol Chem275 :30844 –30848,2000
      21. Cosgrove D, Meehan DT, Grunkemeyer JA, Kornak JM, Sayers R, Hunter WJ, Samuelson GC: Collagen COL4A3 knockout: A mouse model for autosomal Alport syndrome. Genes Dev10 :2981 –2992,1996
      22. Miner JH, Sanes JR: Molecular and functional defects in kidneys of mice lacking collagen alpha 3(IV): Implications for Alport syndrome. J Cell Biol135 :1403 –1413,1996
      23. Boutaud A, Borza DB, Bondar O, Gunwar S, Netzer KO, Singh N, Ninomiya Y, Sado Y, Noelken ME, Hudson BG: Type IV collagen of the glomerular basement membrane: Evidence that the chain specificity of network assembly is encoded by the noncollagenous NC1 domains. J Biol Chem275 :30716 –30724,2000
      24. Andrews KL, Mudd JL, Li C, Miner JH: Quantitative trait loci influence renal disease progression in a mouse model of Alport syndrome. Am J Pathol160 :721 –730,2002
      25. Lambert C, Leonard N, De Bolle X, Depiereux E: ESyPred3D: Prediction of proteins 3D structures. Bioinformatics18 :1250 –1256,2002
      26. Sundaramoorthy M, Meiyappan M, Todd P, Hudson BG: Crystal structure of NC1 domains: Structural basis for type IV collagen assembly in basement membranes. J Biol Chem277 :31142 –31153,2002
      27. Johansson C, Butkowski R, Wieslander J: Characterization of monoclonal antibodies to the globular domain of collagen IV. Connect Tissue Res25 :229 –241,1991
      28. Kalluri R, Cantley LG, Kerjaschki D, Neilson EG: Reactive oxygen species expose cryptic epitopes associated with autoimmune Goodpasture syndrome. J Biol Chem275 :20027 –20032,2000
      29. Borza DB, Bondar O, Colon S, Todd P, Sado Y, Neilson EG, Hudson BG: Goodpasture autoantibodies unmask cryptic epitopes by selectively dissociating autoantigen complexes lacking structural reinforcement: Novel mechanisms for immune privilege and autoimmune pathogenesis. J Biol Chem280 :27147 –27154,2005
      30. David M, Borza DB, Leinonen A, Belmont JM, Hudson BG: Hydrophobic amino acid residues are critical for the immunodominant epitope of the Goodpasture autoantigen. A molecular basis for the cryptic nature of the epitope. J Biol Chem276 :6370 –6377,2001
      31. Lollar P: Pathogenic antibodies to coagulation factors. Part one: Factor VIII and factor IX. J Thromb Haemost2 :1082 –1095,2004
      32. Prescott R, Nakai H, Saenko EL, Scharrer I, Nilsson IM, Humphries JE, Hurst D, Bray G, Scandella D: The inhibitor antibody response is more complex in hemophilia A patients than in most nonhemophiliacs with factor VIII autoantibodies. Recombinate and Kogenate Study Groups. Blood89 :3663 –3671,1997
      33. Gubler MC, Knebelmann B, Beziau A, Broyer M, Pirson Y, Haddoum F, Kleppel MM, Antignac C: Autosomal recessive Alport syndrome: Immunohistochemical study of type IV collagen chain distribution. Kidney Int47 :1142 –1147,1995
      34. Nomura S, Naito I, Fukushima T, Tokura T, Kataoka N, Tanaka I, Tanaka H, Osawa G: Molecular genetic and immunohistochemical study of autosomal recessive Alport’s syndrome. Am J Kidney Dis31 :E4 ,1998
      35. Kalluri R, Torre A, Shield CF 3rd, Zamborsky ED, Werner MC, Suchin E, Wolf G, Helmchen UM, van den Heuvel LP, Grossman R, Aradhye S, Neilson EG: Identification of alpha3, alpha4, and alpha5 chains of type IV collagen as alloantigens for Alport posttransplant anti-glomerular basement membrane antibodies. Transplantation69 :679 –683,2000
      36. Querin S, Noel LH, Grunfeld JP, Droz D, Mahieu P, Berger J, Kreis H: Linear glomerular IgG fixation in renal allografts: Incidence and significance in Alport’s syndrome. Clin Nephrol25 :134 –140,1986
        37. Peten E, Pirson Y, Cosyns JP, Squifflet JP, Alexandre GP, Noel LH, Grunfeld JP, van Ypersele de Strihou C: Outcome of thirty patients with Alport’s syndrome after renal transplantation. Transplantation52 :823 –826,1991
          38. Byrne MC, Budisavljevic MN, Fan Z, Self SE, Ploth DW: Renal transplant in patients with Alport’s syndrome. Am J Kidney Dis39 :769 –775,2002
          39. Kalluri R, Danoff TM, Okada H, Neilson EG: Susceptibility to anti-glomerular basement membrane disease and Goodpasture syndrome is linked to MHC class II genes and the emergence of T cell-mediated immunity in mice. J Clin Invest100 :2263 –2275,1997
          40. Reynolds J, Pusey CD: Oral administration of glomerular basement membrane prevents the development of experimental autoimmune glomerulonephritis in the WKY rat. J Am Soc Nephrol12 :61 –70,2001
          Copyright © 2005 The Authors. Published by Wolters Kluwer Health, Inc. All rights reserved.